Iliac Artery OcclusionNCT04361071
Clinical Study of Stent Versus Direct Atherectomy to Treat Iliac Artery Occlusive Diseases
A study testing stent and plaque excision system in people with Iliac Artery Occlusion, run by Xuanwu Hospital, Beijing at 1 site in China.
Trial summary
This is a randomized study comparing stent and plaque excision systems in treatment of Iliac artery occlusive disease. Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Iliac Artery Occlusion
- What is being tested?
- stent and plaque excision system
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteChina
- Study dates
- 1 Aug 2018to 1 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- The patients have non thrombotic arteriosclerosis obliterans of the common iliac or external iliac arteries
- Clinical diagnosis of stenosis or occlusive disease
- The patients have unobstructed distal outflow tract
- Receiving surgical treatment at the same time
Who cannot join
- The patients who have previously implanted stent(s) or stent graft(s) in target leg
- Life expectancy less than 12 months
- Has any planned surgical or endovascular intervention of target vessel 30 days before or after index procedure
- Thrombophlebitis, uremia, or deep venous thrombus, within past 30 days
- Receiving dialysis or immunosuppressant therapy
- Recent stroke within past 90 days
Show all 14Show fewer
- Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix®) or ticlopidine (Ticlid®), heparin, Nitinol (nickel titanium), contrast agent, that cannot be medically managed
- Tissue loss due to ischemic disease (Rutherford/Becker category 5 or 6)
- Serum creatinine level >/= 2.5 mg/dl at time of screening visit
- Known or suspected active infection at the time of the procedure
- Bleeding diathesis
- Patient is unwilling or unable to comply with procedures specified in the protocol or has difficulty or inability to return for follow-up visits as specified by the protocol.
- Patients are known to be pregnant, incarcerated, mentally incompetent, and/or alcohol or drug abuser.
- Patients are currently participating in any other investigational drug or medical device study that has not completed primary endpoint(s) evaluation or clinically interferes with the endpoints from this study or future participation in such studies prior to the completion of this study.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Yongquan Gu
Beijing, Beijing Municipality, 100053
Jianming Guo, M.D., 13146369562, guojianming@icloud.com
Yongquan Gu, M.D., 15901598209, 15901598209@163.com
About this study
This is a randomized study comparing stent and plaque excision systems in treatment of Iliac artery occlusive disease.
Read the detailed description
This is a randomized study comparing stent and plaque excision systems in treatment of Iliac artery occlusive disease
- Conditions
- Iliac Artery Occlusion
- Being tested
- stent, plaque excision system
- Keywords
- stent, atherectomy, iliac Artery
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
stentDevice
stent
plaque excision systemDevice
plaque excision system
| Study group | Role | What they receive |
|---|---|---|
| Stent | Active comparator | Stent group Receives: Device: stent |
| Atherectomy | Active comparator | Atherectomy group Receives: Device: plaque excision system |
What is being measured
The primary outcome is the main question the study is designed to answer.
12-month Primary Patency Rate
Primary patency is defined as no significant reduction of flow detectable by Duplex ultrasound through the index lesion and no further clinically driven target vessel revascularization performed in the interim. Significant reduction of flow is binary restenosis defined as the diameter stenosis >50% with a peak systolic velocity ratio >2.4 as measured by Duplex ultrasound.
Measured: 12 months
12-month Limb Salvage Rate
Limb Salvage is defined as the freedom from secondary major amputation
Measured: 12 months
Secondary outcomes (3)
Index Limb Ischemia at 6-month Follow up
Index Limb Ischemia is defined by Rutherford/Becker Classification categories 3 through 6.
Measured: 6 months
Index Limb Ischemia at 12-month Follow up
Index Limb Ischemia is defined by Rutherford/Becker Classification categories 3 through 6.
Measured: 12 months
Major Adverse Events at 12-month Post Procedure
Major adverse events included death, index limb ischemia, index limb amputation, clinically driven target lesion revascularization , and significant embolic events, which were defined as causing end-organ damage.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2020
- Study start1 Aug 2018
- Primary completion1 Dec 2022 (estimated)
- Study completion1 Dec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Iliac Artery OcclusionStudies of the same condition, open and under way.
- More trials run by Xuanwu Hospital, BeijingThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Xuanwu Hospital, Beijing
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04361071
- Sponsor's protocol ID
- XuanwuHvas
- Status last verified
- Aug 2019
- First submitted
- 27 Dec 2017
- Last updated
- 24 Apr 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Study of Stent Versus Direct Atherectomy to Treat Iliac Artery Occlusive Diseases
- ClinicalTrials.gov ID
- NCT04361071
- Acronym / sponsor ID
- XuanwuHvas
- Conditions
- Iliac Artery Occlusion
- Keywords
- stent, atherectomy, iliac Artery
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Xuanwu Hospital, BeijingUniversity, hospital or other
- Study start
- 1 Aug 2018 (actual)
- Primary completion
- 1 Dec 2022 (estimated)
- Study completion
- 1 Dec 2023 (estimated)
- First posted
- 24 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized study comparing stent and plaque excision systems in treatment of Iliac artery occlusive disease.
Detailed description
This is a randomized study comparing stent and plaque excision systems in treatment of Iliac artery occlusive disease
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Stent | Active comparator | Device: stentStent group |
| Atherectomy | Active comparator | Device: plaque excision systemAtherectomy group |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- The patients have non thrombotic arteriosclerosis obliterans of the common iliac or external iliac arteries
- Clinical diagnosis of stenosis or occlusive disease
- The patients have unobstructed distal outflow tract
- Receiving surgical treatment at the same time
Key exclusion criteria (14 listed)
- The patients who have previously implanted stent(s) or stent graft(s) in target leg
- Life expectancy less than 12 months
- Has any planned surgical or endovascular intervention of target vessel 30 days before or after index procedure
- Thrombophlebitis, uremia, or deep venous thrombus, within past 30 days
- Receiving dialysis or immunosuppressant therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| stentstent | Device | Stent |
| plaque excision systemplaque excision system | Device | Atherectomy |
Primary outcome
12-month Primary Patency Rate
Time frame: 12 months
Primary patency is defined as no significant reduction of flow detectable by Duplex ultrasound through the index lesion and no further clinically driven target vessel revascularization performed in the interim. Significant reduction of flow is binary restenosis defined as the diameter stenosis >50% with a peak systolic velocity ratio >2.4 as measured by Duplex ultrasound.
12-month Limb Salvage Rate
Time frame: 12 months
Limb Salvage is defined as the freedom from secondary major amputation
3 secondary outcomes
Index Limb Ischemia at 6-month Follow up
Time frame: 6 months
Index Limb Ischemia at 12-month Follow up
Time frame: 12 months
Major Adverse Events at 12-month Post Procedure
Time frame: 12 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2020.
Related trials for Iliac Artery Occlusion
Active, not recruitingObservational study
External Iliac Artery Endofibrosis in Cycling
Iliac Artery Occlusive Disease, Blood Flow Velocity
Active, not recruitingObservational study
Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry
Peripheral Artery Disease, Popliteal Aneurysm
RecruitingObservational study
An Observational Study to Evaluate Safety, Performance, and Clinical Benefit of BeFlow
Iliac Artery Stenosis, Iliac Artery Occlusion
RecruitingObservational study
Predictors of Major Adverse Limb Events After Endovascular Iliac Stenting: a Real-world Cohort Study
Peripheral Arterial Disease, Aortoiliac Occlusive Disease
RecruitingObservational study
GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Post-Market Clinical Follow-Up (PMCF) Observational Registry (RE-PROVE)
Aorto-iliac Occlusive Disease (AIOD), Visceral Artery Occlusive Disease (VAOD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing stent and plaque excision system in people with Iliac Artery Occlusion, run by Xuanwu Hospital, Beijing at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 24 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Jianming Guo, M.D. (13146369562, guojianming1020@icloud.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
12-month Primary Patency Rate (time frame: 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2020.